Jenscare Scientific Reports Promising TRAVEL II Study Results
Company Announcements

Jenscare Scientific Reports Promising TRAVEL II Study Results

Jenscare Scientific Co. Ltd. Class H (HK:9877) has released an update.

Jenscare Scientific Co., Ltd. has announced promising results from its TRAVEL II study, showcasing the LuX-Valve Plus system’s impressive efficacy and safety in treating severe tricuspid regurgitation. With a high device success rate of 97% and significant improvements in patients’ quality of life, these findings highlight the potential of Jenscare’s innovative medical solutions.

For further insights into HK:9877 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App